Stocks · News reference
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
Read original at benzingaFiled: 2026-08-18 AccNo: 0001213900-26-091002 Size: 190 KB Item 3.02: Unregistered Sales of Equity Securities
Read original at edgar